H.C. Wainwright Downgrades Acelyrin Inc (SLRN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- BuzzFeed cuts 35% of workforce in restructuring move
Acelyrin Inc (SLRN) PT Lowered to $6 at Citi
August 14, 2024 9:25 AM EDTCiti analyst Samantha Semenkow lowered the price target on Acelyrin Inc (NASDAQ: SLRN) to $6.00 (from $8.00) while maintaining a Neutral rating.
The analyst comments "Acelyrin announced a strategic reprioritization to focus resources on development of lonigutamab (anti-IGFR1) in thyroid eye disease. The company will... More
